These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 37474083)

  • 21. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
    Han X; Li H; Zhou D; Chen Z; Gu Z
    Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-κB inhibitor for antitumor immunotherapy.
    Xiao Z; Su Z; Han S; Huang J; Lin L; Shuai X
    Sci Adv; 2020 Feb; 6(6):eaay7785. PubMed ID: 32076650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nano-Econazole Enhanced PD-L1 Checkpoint Blockade for Synergistic Antitumor Immunotherapy against Pancreatic Ductal Adenocarcinoma.
    Li Q; Qin S; Tian H; Liu R; Qiao L; Liu S; Li B; Yang M; Shi J; Nice EC; Li J; Lang T; Huang C
    Small; 2023 Jun; 19(23):e2207201. PubMed ID: 36899444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Codelivery of Anti-PD-1 Antibody and Paclitaxel with Matrix Metalloproteinase and pH Dual-Sensitive Micelles for Enhanced Tumor Chemoimmunotherapy.
    Su Z; Xiao Z; Wang Y; Huang J; An Y; Wang X; Shuai X
    Small; 2020 Feb; 16(7):e1906832. PubMed ID: 31990457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
    Ma Z; Zhang W; Dong B; Xin Z; Ji Y; Su R; Shen K; Pan J; Wang Q; Xue W
    Theranostics; 2022; 12(11):4965-4979. PubMed ID: 35836810
    [No Abstract]   [Full Text] [Related]  

  • 26. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
    Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Novel PD-L1-Containing MSLN Targeting Vaccine for Lung Cancer Immunotherapy.
    Zeng W; Pan J; Fang Z; Jia J; Zhang R; He M; Zhong H; He J; Yang X; Shi Y; Zhong B; Zeng J; Fu B; Huang M; Liu H
    Front Immunol; 2022; 13():925217. PubMed ID: 35795680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Redox-Triggered Autophagy-Induced Nanoplatform with PD-L1 Inhibition for Enhancing Combined Chemo-Immunotherapy.
    Li M; Zhao D; Yan J; Fu X; Li F; Liu G; Fan Y; Liang Y; Zhang X
    ACS Nano; 2024 May; 18(20):12870-12884. PubMed ID: 38727063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted Ultrasound Nanobubbles Therapy for Prostate Cancer via Immuno-Sonodynamic Effect.
    Huang X; Chen Y; Zhong F; Gui B; Hu Y; Guo Y; Deng Q; Zhou Q
    Int J Nanomedicine; 2024; 19():2793-2806. PubMed ID: 38525011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy.
    Elia AR; Grioni M; Basso V; Curnis F; Freschi M; Corti A; Mondino A; Bellone M
    Clin Cancer Res; 2018 May; 24(9):2171-2181. PubMed ID: 29490991
    [No Abstract]   [Full Text] [Related]  

  • 31. Injectable microenvironment-responsive hydrogels with redox-activatable supramolecular prodrugs mediate ferroptosis-immunotherapy for postoperative tumor treatment.
    Cheng Z; Xue C; Liu M; Cheng Z; Tian G; Li M; Xue R; Yao X; Zhang Y; Luo Z
    Acta Biomater; 2023 Oct; 169():289-305. PubMed ID: 37544392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Construction of a core-shell microneedle system to achieve targeted co-delivery of checkpoint inhibitors for melanoma immunotherapy.
    Yang P; Lu C; Qin W; Chen M; Quan G; Liu H; Wang L; Bai X; Pan X; Wu C
    Acta Biomater; 2020 Mar; 104():147-157. PubMed ID: 31904558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
    Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A tumor targeted nano micelle carrying astragaloside IV for combination treatment of bladder cancer.
    Kong C; Sun J; Hu X; Li G; Wu S
    Sci Rep; 2024 Jul; 14(1):17704. PubMed ID: 39085255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD4
    Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cryo-Nanocatalyst Enhances Therapeutic Efficacy of Cryo-Immunotherapy through Necroptosis and Local Delivery of Programmed Death-Ligand 1 Inhibitors.
    Lee S; Ko MJ; Avritscher R; Lewandowski RJ; Kim DH
    ACS Nano; 2024 Sep; 18(35):24269-24282. PubMed ID: 39175187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
    Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PEG-Sheddable Nanodrug Remodels Tumor Microenvironment to Promote Effector T Cell Infiltration and Revise Their Exhaustion for Breast Cancer Immunotherapy.
    Huang T; Zhang Q; Yi J; Wang R; Zhang Z; Luo P; Zeng R; Wang Y; Tu M
    Small; 2023 Sep; 19(38):e2301749. PubMed ID: 37211704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer.
    Wang YM; Qiu JJ; Qu XY; Peng J; Lu C; Zhang M; Zhang MX; Qi XL; Lv B; Guo JJ; Guo CY; Li GL; Hua KQ
    Oncoimmunology; 2022; 11(1):2034257. PubMed ID: 35154907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PGC-1α activator-induced fatty acid oxidation in tumor-infiltrating CTLs enhances effects of PD-1 blockade therapy in lung cancer.
    Wan H; Xu B; Zhu N; Ren B
    Tumori; 2020 Feb; 106(1):55-63. PubMed ID: 31451071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.